左甲状腺素对甲状腺过氧化物酶抗体阴性的亚临床甲状腺功能减退孕妇的影响
在德黑兰甲状腺与妊娠研究框架下开展的单盲随机临床试验,纳入366例甲状腺过氧化物酶抗体阴性的亚临床甲状腺功能减退(SCH-TPOAb-)孕妇和1092例甲状腺功能正常TPOAb-孕妇。SCH-TPOAb-孕妇随机分为左甲状腺素(LT4)治疗组(A组,n=183)和无治疗组(B组,n=183),甲状腺功能正常组(C组,n=1028)作为对照。以2.5 mIU/L为TSH切点时,A组与B组早产率无显著差异(RR 0.86,95%CI 0.47-1.55,P=0.61);但基于4.0 mIU/L切点的log-binomial模型分析显示,LT4治疗组早产率显著低于无治疗组(RR 0.38,95%CI 0.15-0.98,P=0.04)。
要点
- 以TSH 2.5 mIU/L为切点时,LT4治疗未显著降低SCH-TPOAb-孕妇的早产率(RR 0.86,95%CI 0.47-1.55,P=0.61)。
- 基于TSH 4.0 mIU/L切点的分析显示,LT4治疗组早产率显著低于无治疗组(RR 0.38,95%CI 0.15-0.98,P=0.04)。
- 作者结论认为,对于TSH在2.5至4 mIU/L之间的SCH-TPOAb-孕妇,LT4对减少早产无有益效果,但使用新推荐的≥4.0 mIU/L切点时LT4可精确降低该并发症。
核心结论
- 尽管LT4治疗对TSH切点为2.5至4 mIU/L的SCH-TPOAb-孕妇在降低早产方面无有益效果,但使用新推荐的≥4.0 mIU/L切点时LT4可精确降低该并发症。
研究设计与样本
- 本研究在德黑兰甲状腺与妊娠研究框架内开展,为单盲随机临床试验,在Shahid Beheshti医科大学产前保健中心进行。
- 采用促甲状腺激素(TSH)切点2.5 mIU/L,招募366例SCH-TPOAb-孕妇和1092例甲状腺功能正常TPOAb-孕妇。
- SCH-TPOAb-孕妇随机分为A组(n=183,接受LT4治疗)和B组(n=183,不接受治疗),1028例甲状腺功能正常TPOAb-孕妇作为对照组(C组)。
主要发现
- 采用TSH切点2.5 mIU/L时,A组与B组早产率无显著差异(RR 0.86,95%CI 0.47-1.55,P=0.61)。
- 基于4.0 mIU/L切点的log-binomial模型分析显示,LT4治疗组早产率显著低于无治疗组(RR 0.38,95%CI 0.15-0.98,P=0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Currently, there is no consensus on universal thyroid screening and levothyroxine (LT4) treatment of pregnant women with subclinical hypothyroidism (SCH) who are negative for thyroid peroxidase antibody (TPOAb-). OBJECTIVE: We aimed to evaluate the benefits of LT4 treatment on pregnancy outcomes in SCH-TPOAb- women. DESIGN: This study was conducted within the framework of the Tehran Thyroid and Pregnancy Study. A single-blind randomized clinical trial was undertaken in pregnant women who were SCH-TPOAb-. SETTING: Prenatal care centers of the Shahid Beheshti University of Medical Sciences. PATIENTS: Using the thyrotropin (TSH) cut point of 2.5 mIU/L, 366 SCH-TPOAb- and 1092 euthyroid TPOAb- women were recruited. INTERVENTION: SCH-TPOAb- women were randomly assigned to two groups: group A (n = 183) who were treated with LT4 and group B (n = 183) who received no treatment. A total of 1,028 euthyroid TPOAb- women served as the control group (group C). MAIN OUTCOME MEASURE: The primary outcome was the rate of preterm delivery. RESULTS: Using the TSH cutoff of 2.5 mIU/L, no significant difference in preterm delivery was observed between groups A and B [relative risk (RR): 0.86; 95% confidence interval (CI): 0.47 to 1.55; P = 0.61]. However, log-binomial model analysis based on a cut point of 4.0 mIU/L demonstrated a significantly lower rate of preterm delivery in LT4-treated women compared with those who received no treatment (RR: 0.38; 95% CI: 0.15 to 0.98; P = 0.04). CONCLUSIONS: Despite no beneficial effect of LT4 therapy in reducing preterm delivery in SCH-TPOAb- women with a TSH cut point of 2.5 to 4 mIU/L, LT4 could precisely decrease this complication using the newly recommended cutoff ≥4.0 mIU/L.
引用
- Nazarpour S, Ramezani Tehrani F, Simbar M, et al. Effects of Levothyroxine on Pregnant Women With Subclinical Hypothyroidism, Negative for Thyroid Peroxidase Antibodies. J Clin Endocrinol Metab. 2018. PMID: 29126290. doi:10.1210/jc.2017-01850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。